Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

Tanezumab Reduces Pain in a Variety of Chronic Pain Conditions: Presented at AAPM By Jennifer Reising SAN ANTONIO, Tex -- February 8, 2010 -- Tanezumab effectively and safely reduces pain associated with osteoarthritis (OA), interstitial cystitis, and chronic low back pain, according to a review of studies presented here at the 26th annual meeting of the American Academy of Pain Medicine (AAPM). “We see that tanezumab improves pain across a variety of chronic pain states, especially chronic low back pain and interstitial cystitis, which are 2 very difficult chronic pain conditions to treat,” said Leslie Tive, PhD, Pfizer, Inc., New York, New York, on February 3. Tanezumab is a humanised, anti-nerve growth factor antibody. Dr. Tive and colleagues reviewed results from 3 randomised, double-blind, placebo-controlled, 16-week trials, each conducted in 1 of 3 pain conditions: OA of the knee, chronic low back pain, and interstitial cystitis. The studies examined changes from baseline in pain following single or multiple tanezumab doses in a total of 725 patients. The OA study was a multiple-dose study; patients were randomised to receive 1 intravenous (IV) infusion of tanezumab (10, 25, 50,100 or 200 mcg/kg) or placebo twice during the study, separated by an 8-week interval. In the chronic low back pain study, patients were randomised to receive a single IV infusion of tanezumab (200 mcg/kg), naproxen 500 mg BID, or placebo. Patients with interstitial cystitis were randomised to receive tanezumab (200 mcg/kg) or placebo. Each clinical trial showed clinically significant pain reduction, as defined by >=30% reduction from baseline in index pain in the OA and low back pain studies and a change from baseline in the average daily pain score of >=1 point over placebo in the interstitial cystitis study. Improvements in pain were greater with tanezumab than with placebo in the OA and low back pain studies (P < .05), and greater with tanezumab compared with naproxen in the low back pain study as well (P = .004). Adverse events (AEs) were generally as expected for respective study populations with few rated as serious (0%-5.9%). AEs of abnormal peripheral sensation were reported by 13.5% of tanezumab-treated patients in the OA study, 12.5% in the chronic low back pain study, and 29.4% in the interstitial cystitis study. AEs were generally transient and not associated with substantial or clinically meaningful neurological deficits. Funding for this study was provided by Pfizer, Inc. [Presentation title: Tanezumab, a Humanized Anti-Nerve Growth Factor Antibody in the Treatment of Three Chronic Pain Types. Abstract 151] E-mail this page to a friend or colleague! To print, use this version